ÂÜÀòÂÒÂ×

Yajun Xu is currently president of Hongsen Investment Group. She also serves as Sr. Advisor for Shangbay Capital, co-founder of Epimab Inc., and board member and advisor on numerous biotech companies in U.S. and China. Previously, she was Sr. Vice President of corporate development at Shangpharma, Executive Vice President of biology and pre-clinical service at Chempartner in Shanghai, China. Prior to Joining Shangpharma, Yajun was director of inflammation at Millennium pharma Inc. and senior scientist at BASF Bioresearch Corp. (now AbbVie Bioresearch Corp.). She received her Ph.D. in Biochemistry at Brandeis University and postdoctoral training at Harvard School of Public Health.